Schubert Jonckheer & Kolbe
Representing Shareholders, Employees, and Consumers for Over 30 Years
MiMedx_logo_CMYK.png

News

News & Investigations

News and Investigations

We're actively investigating new cases on behalf of consumers, employees, and shareholders. If you've purchased any of these consumer products or own stock in any of these companies, please contact us to discuss your legal rights.

 

Geron Corporation Officers and Directors Under Investigation for False Statements and Insider Trading

Geron image.jpg

Schubert Jonckheer & Kolbe LLP is investigating potential derivative claims on behalf of shareholders of Geron Corporation (NASDAQ: GERN) relating to possible false statements to investors and insider trading by an officer and a director. 

A securities class action against the company in the U.S. District Court for the Northern District of California recently survived a motion to dismiss allegations that between March 19 and September 26, 2018, Geron and its CEO made false and misleading statements about the effectiveness of the drug imetelstat, which was then under study for the treatment of myelofibrosis, a rare blood cancer. Geron’s stock price cratered when the company’s development partner, Janssen Biotech, pulled out of the imetelstat partnership on September 27, 2018, wiping out hundreds of millions of dollars of shareholder value. During the same time period, two high-level Geron insiders sold more than $7.3 million of company stock while outside investors remained unaware of the truth about imetelstat’s effectiveness.

The Schubert Firm is investigating potential breaches of fiduciary duty by the company’s officers and directors in connection with these allegations.

If you currently own stock in Geron and wish to obtain additional information—or would like to participate in a potential shareholder derivative action—please complete the form below for a free legal consultation.

InvestigationsAmber SchubertInvestigations